Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
Krzysztof Mrózek(The Ohio State University), Ann‐Kathrin Eisfeld, Wendy Stock(University of Chicago), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Shelley Orwick(St. Jude Children's Research Hospital), Christopher C. Oakes(The Ohio State University), Maria R. Baer(University of Maryland, Baltimore), Jessica Kohlschmidt(The Ohio State University), Guido Marcucci(City of Hope), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Kellie J. Archer(The Ohio State University), Andrew J. Carroll(University of Alabama at Birmingham), James S. Blachly(The Ohio State University Wexner Medical Center), Deedra Nicolet(The Ohio State University), Karilyn Larkin(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), John C. Byrd(University of Cincinnati), Bayard L. Powell(Atrium Health Wake Forest Baptist), William Blum(The Ohio State University)
Cited by 76
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k